Low expression of RGL4 is associated with a poor prognosis and immune infiltration in lung adenocarcinoma patients

• Published in: International immunopharmacology Vol. 83; p. 106454
• Main Authors: Sun, Yidan, Zhang, Ying, Ren, Shiqi, Li, Xiaojiang, Yang, Peiying, Zhu, Jinli, Lin, Lisen, Wang, Ziheng, Jia, Yingjie
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2020; Elsevier BV
• Subjects: Adenocarcinoma; Adenocarcinoma - diagnosis; Adenocarcinoma - metabolism; Adenocarcinoma - mortality; B-Lymphocytes - immunology; Bioinformatics; Biomarkers; Cancer; CD8 antigen; CD8-Positive T-Lymphocytes - immunology; Cell Movement; Female; Gene Expression Regulation, Neoplastic; Genomes; Gluconeogenesis; Glycolysis; Health risks; Humans; Immune checkpoint; Immune infiltrate; Immune system; Immunological memory; Immunotherapy; Infiltration; Leukocytes (neutrophilic); Lung - immunology; Lung Adenocarcinoma; Lung Neoplasms - diagnosis; Lung Neoplasms - metabolism; Lung Neoplasms - mortality; Lungs; Lymphocytes; Lymphocytes B; Lymphocytes T; Male; Medical prognosis; Memory cells; Metastases; Middle Aged; Morbidity; p53 Protein; Prognosis; ral Guanine Nucleotide Exchange Factor - genetics; ral Guanine Nucleotide Exchange Factor - metabolism; RGL4; Ribonucleic acid; RNA; Signal Transduction; Signaling; Survival Analysis; TCGA; Tumor Suppressor Protein p53 - metabolism; Tumor-infiltrating lymphocytes; Biomarkers; Lung Adenocarcinoma; Immune infiltrate; RGL4; Bioinformatics; TCGA
• ISSN: 1567-5769; 1878-1705; 1878-1705
• DOI: 10.1016/j.intimp.2020.106454

•No studies have reported any correlation between RGL4 and tumor survival prognosis.•RGL4 may have broad research value in the pathogenesis, pathological status and prognosis of various tumors.•RGL4 affects immune cell abundance in lung adenocarcinoma microenvironment.•RGL4 may have potential application value in inducing or avoiding immunosuppression.•RGL4 can be used as an auxiliary marker in combination with immune checkpoints to screen the benefit of immunotherapy. Lung adenocarcinoma (LUAD) is a frequently diagnosed histologic subtype with increasing morbidity and mortality. RalGDS-Like 4 (RGL4) has not been reported to be associated with cancer risk, prognosis, immunotherapy or any other treatments. We perform a bioinformatics analysis on data downloaded from the Cancer Genome Atlas (TCGA)-LUAD, and we find that low expression of RGL4 is accompanied by worse outcomes and prognosis in LUAD patients. As a promising predictor, the potential influence and mechanisms of RGL4 on overall survival are worth exploring. Moreover, RGL4 expression is significantly associated with a variety of tumor-infiltrating immune cells (TIICs), particularly memory B cells, CD8+T cells and neutrophils. Subsequently, we evaluated the most notable KEGG pathways, including glycolysis gluconeogenesis, the P53 signaling pathway, RNA degradation, and the B cell receptor signaling pathway, among others. Our findings provide evidence that the decreased expression of RGL4 is significantly associated with poor prognosis and immune cell infiltration in patients with LUAD and highlight the use of RGL4 as a novel predictive biomarker for the prognosis of LUAD and other cancers. RGL4 may also be used in combination with immune checkpoints to identify the benefits of immunotherapy. Subjects: Bioinformatics, Genomics, Oncology, Thoracic surgery.